CordenPharma Colorado to scale peptide development at new LEED Gold facility

USA—CordenPharma Colorado has secured a 64,000-square-foot facility at BioMed Realty’s Flatiron Park in Boulder, marking a significant expansion of the company’s peptide development capabilities.

The 15-year lease covers the entire premises at 5505 Central, Boulder’s first purpose-built speculative laboratory building designed specifically for life sciences operations.

The LEED Gold-certified facility features flexible laboratory configurations and advanced mechanical and utility systems, enabling researchers to conduct intricate scientific research.

The building’s sophisticated waste management infrastructure supports the complex requirements of pharmaceutical development work.

Seamless integration with existing operations

The new location sits adjacent to CordenPharma Colorado’s existing peptide manufacturing site, creating an integrated campus that streamlines operations from early-stage development through commercial production.

This proximity allows the company to offer comprehensive process development and analytical services while maintaining close coordination with its manufacturing operations.

The strategic positioning enables scientists to move peptide active pharmaceutical ingredients smoothly through the development pipeline toward commercialization, reducing transfer times and maintaining quality standards throughout the process.

Growing life sciences hub

BioMed Realty’s Flatiron Park campus hosts a diverse mix of life science, quantum computing, and technology companies.

The development provides resilient infrastructure and adaptable building solutions designed to accommodate the evolving needs of innovative organizations.

Jon Bergschneider, BioMed Realty’s West Coast markets president, emphasized the facility’s design philosophy.

“We’re proud to deliver the first purpose-built lab building at Flatiron Park, designed to meet the flexibility and performance needs of sophisticated science users,” he stated.

The campus offers tenants a connected environment with curated amenities, Discover Here programming, and a tenant-focused operating model that supports both immediate innovation needs and long-term expansion plans.

Meeting market demand

Michael Landau, managing director of CordenPharma Colorado, expressed enthusiasm about the partnership with BioMed Realty.

The expansion accelerates the company’s strategic growth trajectory while addressing increasing customer demand for complex peptide outsourcing services.

The project creates additional employment opportunities and attracts research talent to the Boulder region.

“With our strong team and strategic vision, backed by our global facility network, these new labs will grow the life sciences sector in Boulder,” Landau explained.

As a contract development and manufacturing organization, the company views its development laboratories as essential infrastructure for delivering effective support to customers and their patients.

The enhanced peptide development facility integrates into CordenPharma’s worldwide network, which spans multiple locations across Europe and the United States, strengthening the company’s global service capabilities.